CHMFL-ABL/KIT-155
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


CHMFL-ABL/KIT-155
Description :
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis[1].Product Name Alternative :
CHMFL-ABL-KIT-155UNSPSC :
12352005Target :
Apoptosis; Bcr-Abl; c-Kit; Discoidin Domain Receptor; PDGFRType :
Reference compoundRelated Pathways :
Apoptosis; Protein Tyrosine Kinase/RTKApplications :
Cancer-Kinase/proteaseField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/chmfl-abl-kit-155.htmlSolubility :
10 mM in DMSOSmiles :
O=C(N1CCC(OC2=CC(NC(C3=CC=C(CN4CCN(C)CC4)C(C(F)(F)F)=C3)=O)=CC=C2C)CC1)C5=CC=C(C)N=C5Molecular Formula :
C33H38F3N5O3Molecular Weight :
609.68References & Citations :
[1]Wang Q, et al. Discovery of 4-Methyl-N- (4- ((4-methylpiperazin-1-yl) methyl) -3- (trifluoromethyl) phenyl) -3- ((1-nicotinoylpiperidin-4-yl) oxy) benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J Med Chem. 2017 Jan 12;60 (1) :273-289.Shipping Conditions :
Room temperatureScientific Category :
Reference compound1Clinical Information :
No Development ReportedCAS Number :
[2081093-21-0]

